Gilead Sciences, Inc.
Gilead Sciences develops and commercializes medicines for unmet medical needs globally. Products include HIV/AIDS treatments Biktarvy, Genvoya, Descovy, etc. Veklury treats COVID-19, while Epclusa, Harvoni, and others treat viral hepatitis. Yescarta, Tecartus, and Trodelvy are oncology treatments. Letairis treats pulmonary arterial hypertension, and AmBisome treats serious fungal infections. The company has multiple collaboration agreements with various partners.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital, an asset-light, cash-generative model, high, stable gross margins (pricing power) and operating margins that held up every year.
- Return on invested capital has stayed above 15% in each of the last 6 years (latest 21.0%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 21.0% against a cost of capital (WACC) of 6.2%, a spread of 14.9 percentage points.
- Pricing power: gross margin has held between 76% and 81% over the last 6 years (latest 78.8%).
- Asset-light, cash-generative model: capital expenditure takes only 2.2% of revenue and free cash flow was positive in each of the last 6 years.
- Improving fundamentals over the last year: return on assets up 13.6 points, gross margin up 0.6 points and asset turnover up 2.3%.
Weaknesses
- Our discounted cash flow target price (126.18 USD) is 25% below the current price.
- More expensive than its own history: P/FCF 22.0x vs. a historical average of 10.8x and EV/EBITDA 15.2x vs. a historical average of 9.2x.
Key Financial Data